United States:
Integrating to Enhance Value and Quality vs. Preserving Competition to Maintain Lower Prices
26 September 2014
Foley & Lardner
To print this article, all you need is to be registered or login on Mondaq.com.
Foley Partner J. Mark Waxman authored a piece for CPI Antitrust
Chronicle's September issue. The article provided insights on
the Affordable Care Act and discussed the need to balance
efficiency and competitiveness within the health care industry.
Materials
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
FDA Ramps Up Actions On PFAS
Holland & Knight
The U.S. Food and Drug Administration (FDA) has increased regulatory activity with regard to per- and polyfluoroalkyl substances (PFAS).
